Glycosylation Signatures of Inflammation Identify Cardiovascular Risk: Some Glyc It Hot

Circulation Research

Volumn 119, Issue 11, 2016, Pages 1154-1156

  Lawler, Patrick R ^a   Mora, Samia ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

anti inflammatory agents; atherosclerosis; Editorials; GlycA; glycosylation; inflammation; metabolomics; psoriasis

Indexed keywords

ANTIINFLAMMATORY AGENT; C REACTIVE PROTEIN; FLUORODEOXYGLUCOSE F 18; TUMOR NECROSIS FACTOR;

CARDIOVASCULAR RISK; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CORONARY ARTERY DISEASE; DISEASE SEVERITY; HUMAN; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; PSORIASIS; REVIEW; VASCULITIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; GLYCOSYLATION; INFLAMMATION; RISK FACTOR;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; GLYCOSYLATION; HUMANS; INFLAMMATION; PSORIASIS; RISK FACTORS;

EID: 84994851014     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.116.310005     Document Type: Review

References (15)

1. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011;473:317-325. doi: 10.1038/ nature10146.
2. Roubille C, Richer V, Starnino T, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74:480-489. doi: 10.1136/annrheumdis-2014-206624.
3. Lauc G. Precision medicine that transcends genomics: glycans as integrators of genes and environment. Biochim Biophys Acta. 2016;1860:1571-1573. doi: 10.1016/j.bbagen.2016.05.001.
4. Connelly MA, Gruppen EG, Otvos JD, Dullaart RP. Inflammatory glycoproteins in cardiometabolic disorders, autoimmune diseases and cancer. Clin Chim Acta. 2016;459:177-186. doi: 10.1016/j.cca.2016.06.012.
5. Otvos JD, Shalaurova I, Wolak-Dinsmore J, Connelly MA, Mackey RH, Stein JH, Tracy RP. GlycA: a composite nuclear magnetic resonance biomarker of systemic inflammation. Clin Chem. 2015;61:714-723. doi: 10.1373/clinchem.2014.232918.
6. Lawler PR, Akinkuolie AO, Chandler PD, Moorthy MV, Vandenburgh MJ, Schaumberg DA, Lee IM, Glynn RJ, Ridker PM, Buring JE, Mora S. Circulating N-linked glycoprotein acetyls and longitudinal mortality risk. Circ Res. 2016;118:1106-1115. doi: 10.1161/ CIRCRESAHA.115.308078.
7. Ala-Korpela M. Serum nuclear magnetic resonance spectroscopy: one more step toward clinical utility. Clin Chem. 2015;61:681-683. doi: 10.1373/clinchem.2015.238279.
8. Akinkuolie AO, Buring JE, Ridker PM, Mora S. A novel protein glycan biomarker and future cardiovascular disease events. J Am Heart Assoc. 2014;3:e001221. doi: 10.1161/JAHA.114.001221.
9. Akinkuolie AO, Glynn RJ, Padmanabhan L, Ridker PM, Mora S. Circulating N-linked glycoprotein side-chain biomarker, rosuvastatin therapy, and incident cardiovascular disease: an analysis from the JUPITER Trial. J Am Heart Assoc. 2016;5:e003822. doi: 10.1161/ JAHA.116.003822.
10. Würtz P, Havulinna AS, Soininen P, et al. Metabolite profiling and cardiovascular event risk: a prospective study of 3 population-based cohorts. Circulation. 2015;131:774-785. doi: 10.1161/ CIRCULATIONAHA.114.013116.
11. Akinkuolie AO, Pradhan AD, Buring JE, Ridker PM, Mora S. Novel protein glycan side-chain biomarker and risk of incident type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2015;35:1544-1550. doi: 10.1161/ATVBAHA.115.305635.
12. Fischer K, Kettunen J, Würtz P, et al. Biomarker profiling by nuclear magnetic resonance spectroscopy for the prediction of all-cause mortality: an observational study of 17,345 persons. PLoS Med. 2014;11:e1001606. doi: 10.1371/journal.pmed.1001606.
13. Duprez DA, Otvos J, Sanchez OA, Mackey RH, Tracy R, Jacobs DR Jr. Comparison of the predictive value of GlycA and other biomarkers of inflammation for total death, incident cardiovascular events, noncardiovascular and noncancer inflammatory-related events, and total cancer events. Clin Chem. 2016;62:1020-1031. doi: 10.1373/clinchem.2016.255828.
14. Ritchie SC, Würtz P, Nath AP, et al. The biomarker GlycA is associated with chronic inflammation and predicts long-term risk of severe infection. Cell Syst. 2015;1:293-301. doi: 10.1016/j.cels.2015.09.007.
15. Joshi AA, Lerman JB, Aberra TM, et al. GlycA is a novel biomarker of inflammation and subclinical cardiovascular disease in psoriasis. Circ Res. 2016;119:1242-1253. doi: 10.1161/CIRCRESAHA.116.309637.